{"disease":{"id":"renal-cell-carcinoma-clear-cell-somatic","name":"renal cell carcinoma clear cell somatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06317298","title":"Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Peking University First Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}